Theriva Biologics, Inc. TOVX 深 沪
已收盘 02-06 16:00:00 美东时间
0.22
+0.020
+10.06%
华盛通- 最 高0.22
- 今 开0.20
- 成交量 237.20万股
- 最 低 0.1912
- 昨 收 0.1999
- 总市值 785.14万
- 52周最高 1.75
- 市盈率 静 --
- 换手率 6.65%
- 52周最低 0.1651
- 委 比 33.33%
- 总股本 3568.83万
- 历史最高 37800.00
- 量 比 1.01
- 振 幅 14.41%
- 历史最低 0.1651
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Theriva Biologics announced the presentation of Phase 1 clinical data for VCN-01 in refractory retinoblastoma patients at the 41st APAO Congress in Hong Kong on Feb. 7, 2026. The study highlights the safety and efficacy of intravitreal VCN-01 injections in children with treatment-resistant intraocular retinoblastoma. Preclinical data also show synergistic antitumor activity when VCN-01 is combined with topotecan, potentially improving outcomes fo...
02-03 13:00
Why Is Theriva Biologics Stock Gaining Monday?
Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.
2025-12-30 00:41
Theriva Biologics Gains EMA Backing for VCN-01 Phase 3
Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Th...
2025-12-29 21:33
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Theriva Biologics announced receipt of scientific advice from the EMA's CHMP regarding the design of a pivotal Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic PDAC. The EMA agreed on the proposed trial design, including sample size, dosing regimen, and adaptive design to optimize outcomes. Theriva plans to schedule an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize...
2025-12-29 13:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 9.3% to $...
2025-12-24 05:05
Theriva Biologics Reschedules Special Stockholder Meeting
Theriva Biologics ( ($TOVX) ) has provided an announcement. On December 15, 202...
2025-12-16 07:25
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06
Theriva Biologics Q3 EPS $(0.45) Beats $(1.13) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.13) by 60.18 percent. This is a 93.39 percent increase over losses of $(6.81) per share from
2025-11-12 21:14
Theriva Biologics Addresses Unusual NYSE Trading Activity; Confirms No New Developments Since VIRAGE Trial Data Presentation At ESMO 2025
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today
2025-10-25 02:35
Theriva Biologics Provides Response to Unusual Market Action
<p>Theriva Biologics announced unusual trading activity in its common stock on the NYSE American on October 24, 2025, and released a press statement under Section 401(d) of the NYSE Company Guide. The company conducted inquiries and concluded no corrective actions are necessary. No material developments or undisclosed events were identified as reasons for the market action. However, on October 13, 2025, the company presented expanded data from it...
2025-10-24 18:31
